Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Elevated Blood Pressure
Interventions: Stress Management; Behavioral
Lead sponsor: Michigan Technological University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Hammond, Indiana

Conditions: Hypertension, Plasma Renin Activity
Interventions: Hydrochlorothiazide, Lisinopril, Amlodipine, metoprolol, lisinopril/hydrochlorothiazide; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Intervention, Active Comparator; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Ischemic Stroke, Hemorrhagic Stroke
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 5 more

Conditions: Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension, Lung Diseases, Tamoxifen, Estrogen Receptor Antagonist, Hormone Antagonists, Estrogens
Interventions: Tamoxifen, Placebo Oral Tablet; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: Salt-sensitive Hypertension
Interventions: Fenoldopam; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Advanced Chronic Liver Disease, NASH
Interventions: VCTE with splenic stiffness measurement; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertension, Obstructive Sleep Apnea
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 10 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Primary Open Angle Glaucoma, Cataract
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Glendale, Arizona • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Glaucoma
Interventions: Baerveldt Device surgical Procedure; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 5
States / cities: Sacramento, California • Miami, Florida • Baltimore, Maryland + 2 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Latanoprost; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Cardiovascular Diseases
Interventions: Fruit and vegetable supplement, Dietary and chronic disease management education; Dietary Supplement · Behavioral
Lead sponsor: St. Catherine University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Apple Valley, Minnesota • Fridley, Minnesota • Minneapolis, Minnesota + 1 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: Robin, Alan L., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Liver Diseases, Portal Hypertension
Interventions: SHAPE measurement (Sonazoid ultrasoud contrast agent); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Minocycline; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2,072 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension
Interventions: baxdrostat (formerly CIN-107) oral solution; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Megan Ballinger; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Exercise-induced Pulmonary Arterial Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Mindfulness and Neural Cardiovascular Control in Humans

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Enhancing Systems of Care to Improve Hypertension Guideline Implementation

Mapping the Natural History of Parenychymal and Cerebral Perfusion Changes in Acute Ischemic and Hemorrhagic Strokes

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

Milrinone in Congenital Diaphragmatic Hernia

Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Non-invasive Evaluation of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease by Assessment of Spleen Stiffness Using VCTE by FibroScan.

Hypertension and Sleep Disordered Breathing in Pediatrics

Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent

Baerveldt Plate Area Comparison (BPAC)

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Increased Access to Fruits and Vegetables for Hypertension in Immigrant Hispanic/Latinx Individuals

An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension

Study 3: Minocycline Decreases Microglia Activation

Cardiovascular Disease Risk Factors in Chinese American Immigrants

Baxdrostat Bioavailability and Bioequivalence Study

The Expression and Significance of MiRNA

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)